<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35129">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01886820</url>
  </required_header>
  <id_info>
    <org_study_id>NAV4-02</org_study_id>
    <nct_id>NCT01886820</nct_id>
  </id_info>
  <brief_title>A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology</brief_title>
  <official_title>A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navidea Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navidea Biopharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Determine the the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral
      Î²-Amyloid When Compared With Postmortem Histopathology
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Incidence of [18F]NAV4694 Brain PET scan positivity compared to histopathology</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of [18F]NAV4694 brain PET Scan positivity compared to histopathology</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of [18F]NAV4694 PET Scan positivity in 6 pre-specified brain regions compared to histopathology</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of [18F]NAV4694 PET Scan positivity in 6 pre-specified brain regions compared to histopathology</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Dementia</condition>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>[18F]NAV4694</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous [18F]NAV4694 radioactive dose 8.1 mCi(300 MBq) given once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]NAV4694</intervention_name>
    <arm_group_label>[18F]NAV4694</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects will be at least 21 years of age.

          -  Subjects will have a life expectancy of approximately 6 months.

          -  Female subjects will not be of child-bearing potential or will have a negative urine
             pregnancy test on day of [18F]NAV4694 injection.

          -  Must be able to provide informed consent or assent, and exhibit adequate visual,
             auditory, and communication capabilities to enable compliance with study procedures.
             This includes being able to lie down flat in the MRI and PET scanner for a period of
             approximately 1 hour.

          -  Subjects must be willing to donate their brains for post mortem examination upon
             death (this consent can be obtained in the manner specific to the country/region
             involved).

          -  Subjects have been fully informed about the study, including provisions of the Health
             Insurance Portability and Accountability Act (HIPAA), as applicable, and informed
             consent or assent has been signed and dated (with time) by the subject and/or the
             subject's legally acceptable representative (LAR) (for individuals with dementia).

          -  Subjects who have participated in a previous [18F]NAV4694 study may be included in
             the present study.  The MRI and/or [18F]NAV4694 scan do not need to be repeated if
             they were performed within 12 months prior to inclusion.

        Exclusion Criteria:

          -  Scheduled for surgery and/or another invasive procedure within the time period of up
             to 7 days after [18F]NAV4694 injection.

          -  Has severe cerebral macrovascular (i.e., multi-stroke) disease or brain tumor
             (metastasis/brain cancer) as verified by MRI that prohibits sampling of the required
             pre-specified ROIs.

          -  Has received any contrast material (X-ray, MRI) or radiopharmaceutical within 48
             hours prior to, or a therapeutic radiopharmaceutical (e.g., 131I) within 10 days
             prior to, or any radiopharmaceutical administration within 10 radioactive half-lives
             prior to the administration of the investigational product or for whom administration
             of such substances is planned within 7 days after investigational product
             administration.

          -  Has any contraindication to MRI examination, e.g., metal implants or phobia as
             determined by the on-site radiologist performing the scan.

          -  Is allergic to the investigational product or any of its constituents.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia Reininger, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Navidea Biopharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanna Shuping, BS</last_name>
    <phone>+1-614-822-2388</phone>
    <email>jshuping@navidea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carley Hartings, MPH</last_name>
    <phone>+1-614.973.7558</phone>
    <email>chartings@navidea.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Liebsack</last_name>
      <phone>623-832-6514</phone>
      <email>Carolyn.Liebsack@bannerhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Michele Caverly</last_name>
      <phone>(623) 832-6529</phone>
      <email>Michele.Caverly@bannerhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marwan Sabbagh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Vanderswag</last_name>
      <phone>858-246-1245</phone>
      <email>hvanderswag@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>James Brewer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center of Florida</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isael Santos</last_name>
      <phone>305-674-2018</phone>
      <email>Isael.Santos@msmc.com</email>
    </contact>
    <investigator>
      <last_name>Ranjan Duara, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galiz Research</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Pedraza</last_name>
      <phone>305-805-0921</phone>
      <email>luisp@galizresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jose Gamez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Marsh</last_name>
      <phone>407-210-1310</phone>
      <email>DMarsh@CompassResearch.com</email>
    </contact>
    <investigator>
      <last_name>Ira Goodman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Pluff</last_name>
      <phone>312-563-4111</phone>
      <email>Lindsay_M_Pluff@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Raj Shah, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara C Lokaitis, BA</last_name>
      <phone>217-545-9737</phone>
      <email>blokaitis@siumed.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas A Ala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Las Vegas Radiology</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Bachowska</last_name>
      <phone>702-521-8950</phone>
      <email>joannabachowska@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Bobby Mocherla, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Sollars</last_name>
      <phone>718-405-8363</phone>
      <email>csollars@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Jessica Zwerling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health-Gerontology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Fries</last_name>
      <phone>336-713-8462</phone>
      <email>rfries@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Kaycee Sink, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Terminally Ill</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
